3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Squamous Cell Carcinoma of Head and Neck
2
Neoplasms
2
Vascular Diseases
1
Pathologic Processes
1
Paraproteinemias
1
Pancreatic Neoplasms
1
Neoplastic Processes
1
Neoplasms, Plasma Cell
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Lymphoproliferative Disorders
1
Lymphoma
1
Lymphatic Diseases
1
Liver Neoplasms
1
Liver Diseases
1
Leukemia, Myeloid, Acute
1
Immunoproliferative Disorders
1
Hemorrhagic Disorders
1
Hematologic Diseases
1
Gliosarcoma
1
Glioblastoma
1
Digestive System Neoplasms
1
Digestive System Diseases
1
Cardiovascular Diseases
1
Carcinoma
1
Blood Protein Disorders
1
Interventions
Brentuximab Vedotin
7
dacetuzumab
4
Lenalidomide
3
Doxorubicin
3
Dexamethasone
3
spartalizumab
2
lintuzumab
2
fludarabine
2
Vincristine
2
Rituximab
2
Rifampin
2
Prednisone
2
Gemcitabine
2
Cyclophosphamide
2
tanespimycin
1
sabatolimab
1
pomalidomide
1
pirtobrutinib
1
fludarabine phosphate
1
ficlatuzumab
1
daratumumab
1
Vinblastine
1
Thiotepa
1
TAS4464
1
Sertraline
1
R-CHOP protocol
1
Pam2CSK4 acetate and ODN M362 combination
1
Midazolam
1
Melphalan
1
LCL161
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Hematologic Diseases
×
ficlatuzumab
×
Clear all
NCT00725634
2014-01-27
P05538
AVEO Pharmaceuticals, Inc.
Phase 1
Completed
41 enrolled